offering proceeds, together with the 2015 Term Loan, were used to fund the AMS Portfolio Acquisition.
We recorded a charge of $45 million in interest expense, during the second quarter of 2015, for premiums, accelerated amortization of debt issuance costs, and investor discount costs net of interest rate hedge gains related to the early debt extinguishment.
Our senior notes were issued in public offerings, are redeemable prior to maturity and are not subject to any sinking fund requirements.
Our senior notes are unsecured, unsubordinated obligations and rank on parity with each other.
These notes are effectively junior to borrowings under our credit and security facility, to the extent if borrowed by our subsidiaries, and to liabilities of our subsidiaries (see Other Arrangements below).
On January 12, 2017, we used our existing credit facilities to repay the $250 million plus interest of our senior notes due in January 2017.
Our senior notes consist of the following as of December 31, 2016:
## Table 0 ##
offering proceeds, together with the 2015 Term Loan, were used to fund the AMS Portfolio Acquisition.
We recorded a charge of $45 million in interest expense, during the second quarter of 2015, for premiums, accelerated amortization of debt issuance costs, and investor discount costs net of interest rate hedge gains related to the early debt extinguishment.
Our senior notes were issued in public offerings, are redeemable prior to maturity and are not subject to any sinking fund requirements.
Our senior notes are unsecured, unsubordinated obligations and rank on parity with each other.
These notes are effectively junior to borrowings under our credit and security facility, to the extent if borrowed by our subsidiaries, and to liabilities of our subsidiaries (see Other Arrangements below).
On January 12, 2017, we used our existing credit facilities to repay the $250 million plus interest of our senior notes due in January 2017.
Our senior notes consist of the following as of December 31, 2016: Other Arrangements We maintained a $300 million credit and security facility secured by our U. S.  trade receivables maturing on June 9, 2017.
The credit and security facility required that we maintain a maximum leverage covenant consistent with our revolving credit facility.
The maximum leverage ratio requirement was 4.0 times and our actual leverage ratio as of December 31, 2016 was 2.4 times.
We had borrowings of $60 million outstanding under this facility as of December 31, 2016 and no borrowings outstanding as of December 31, 2015.
On February 7, 2017, we amended the terms of this credit and security facility, including increasing the facility size to $400 million.
This amendment retained a similar maximum leverage ratio requirement and extended the facility maturity to February 2019.
We have accounts receivable factoring programs in certain European countries that we account for as sales under FASB ASC Topic 860, Transfers and Servicing.
These agreements provide for the sale of accounts receivable to third parties, without recourse, of up to approximately $391 million as of December 31, 2016.
We have no retained interests in the transferred receivables, other than collection and administrative responsibilities and, once sold, the accounts receivable are no longer available to satisfy creditors in the event of bankruptcy.
We de-recognized $152 million of receivables as of December 31, 2016 at an average interest rate of 1.8 percent, and $151 million as of December 31, 2015 at an average interest rate of 2.4 percent.
In addition, we have uncommitted credit facilities with a commercial Japanese bank that provide for borrowings, promissory notes discounting and receivables factoring of up to 21.0 billion Japanese yen (approximately $180 million as of December 31, 2016).
We de-recognized $149 million of notes receivable as of December 31, 2016 at an average interest rate of 1.6 percent and $132 million of notes receivable as of December 31, 2015 at an average interest rate of 1.6 percent.
De-recognized accounts and notes receivable are excluded from trade accounts receivable, net in the accompanying consolidated balance sheets.
As of December 31, 2016 and December 31, 2015, we had outstanding letters of credit of $44 million which consisted primarily of bank guarantees and collateral for workers’ compensation insurance arrangements.
As of December 31, 2016 and 2015, none of the beneficiaries had drawn upon the letters of credit or guarantees; accordingly, we have not recognized a related liability for our outstanding letters of credit in our consolidated balance sheets as of December 31, 2016 or 2015.
We repurchased 10 million shares for $125 million during 2014.
No share repurchases were made in 2016 or 2015.
As of December 31, 2016, we had remaining approximately $535 million authorized under our 2013 share repurchase program.
There were approximately 248 million shares in treasury as of December 31, 2016 and December 31, 2015.
Stock-based compensation expense related to our stock ownership plans was $116 million in 2016, $107 million in 2015, and $103 million in 2014.
Stock-based compensation expense varies from period to period based upon, among other factors: the timing, number and fair value of awards granted during the period; forfeiture levels related to unvested awards; and employee contributions to our employee stock purchase plan.
Contractual Obligations and Commitments The following table provides a summary of certain information concerning our obligations and commitments to make future payments, and is based on conditions in existence as of December 31, 2016.
## Table 1 ##
(1) In accordance with U. S.  GAAP, these obligations relate to expenses associated with future periods and are not reflected in our consolidated balance sheets.
(2) Includes accrued interest and penalties and other related items.
The amounts in the table above with respect to lease obligations represent amounts pursuant to contractual arrangements for the lease of property, plant and equipment used in the normal course of business.
Purchase obligations relate primarily to non-cancellable inventory commitments and capital expenditures entered in the normal course of business.
Royalty obligations reported above represent minimum contractual obligations under our current royalty agreements.
The table above does not include $584 million of unrecognized tax benefits and $197 million of accrued interest and penalties, and other related items because the timing of their future cash settlement is uncertain.
Refer to Note J—Income Taxes to our consolidated financial statements included in Item 8 of this Annual Report for more information on these unrecognized tax benefits.
In addition, the table above does not reflect our accrual for legal matters that are probable and estimable of $961 million due to the timing of payment being uncertain.
Refer to Note K—Commitments and Contingencies to our consolidated financial statements included in Item 8 of this Annual Report for more information on our legal accrual.
With certain of our acquisitions, we acquired in-process research and development projects that require future funding to complete the projects.
The primary basis for determining the technological feasibility or completion of these projects is obtaining regulatory approval to market the underlying products in an applicable geographic region.
We estimate that the total remaining cost to complete the in-process research and development projects we acquired is between $25 million and $50 million.
Net cash inflows from the projects currently in development are expected to commence in 2017 through 2030, following the respective launches of these technologies in the U. S. , Europe and Japan.
Certain of our acquisitions also involve the potential payment of contingent consideration.
The table above does not reflect any such obligations, as the timing and amounts are uncertain.
See Note B—Acquisitions and Strategic Investments to our consolidated financial statements included in Item 8 of this Annual Report for the estimated maximum potential amount of future contingent consideration we could be required to pay associated with prior acquisitions and the fair value of our contingent consideration liabilities as of December 31, 2016.
Legal Matters For a discussion of our material legal proceedings see Note K— Commitments and Contingencies to our consolidated financial statements included in Item 8 of this Annual Report.
Critical Accounting Policies and Estimates Our financial results are affected by the selection and application of accounting policies and methods.
We have adopted accounting policies to prepare our consolidated financial statements in conformity with U. S.  GAAP.
To prepare our consolidated financial statements in accordance with U. S.  GAAP, management makes estimates and assumptions that may affect the reported amounts of our assets and liabilities, the disclosure of contingent liabilities as of the date of our financial statements and the reported amounts of our revenues and expenses during the reporting period.
Our actual results may differ from these estimates.
We consider estimates to be critical if (i) we are required to make assumptions about material matters that are uncertain at the time of estimation or if (ii) materially different estimates could have been made or it is reasonably likely that the accounting estimate will change from period to period.
Purchase Price Allocation We accounted for these acquisitions as a business combination and, in accordance with FASB ASC Topic 805, Business Combinations (Topic 850), we recorded the assets acquired and liabilities assumed at their respective fair values as of the acquisition date.
The components of the aggregate preliminary purchase price are as follows (in millions):
## Table 2 ##
The following summarizes the preliminary purchase price allocation for our 2016 acquisitions as of December 31, 2016, (in millions):
## Table 3 ##
We allocated a portion of the preliminary purchase price to specific intangible asset categories as follows:
## Table 4 ##
2015 Acquisitions Interventional Radiology Business of CeloNova Biosciences On December 31, 2015, we completed the acquisition of the interventional radiology business of CeloNova Biosciences (CeloNova), for an upfront payment of $70 million and additional payments contingent on regulatory and sales milestones.
The acquisition includes drug-eluting microspheres designed to be loaded with chemotherapy drugs for delivery to cancerous tumors, and spherical embolic products used to treat uterine fibroids and other conditions.
We are in the process of integrating CeloNova into our Peripheral Interventions business and expect to be substantially complete by the second half of 2017.
AMS Portfolio Acquisition On August 3, 2015, we completed the acquisition of the American Medical Systems male urology portfolio (AMS Portfolio Acquisition), which includes the men’s health and prostate health businesses, from Endo International plc.
Total consideration was comprised of $1.616 billion in up-front cash plus related fees and expenses, and a potential additional $50 million in consideration based on 2016 sales.
The AMS male urology portfolio was integrated with our formerly named Urology and Women’s Health business, and the joint businesses became Urology and Pelvic Health.
The integration was substantially complete by the end of 2016.
In addition, as part of the acquisition agreement, we made a $60 million Series B non-voting preferred stock investment in the women’s health business of Endo Health Solutions, a wholly owned subsidiary of Endo International, plc.
, representing the remaining Women’s Health business of the American Medical Systems’ Portfolio.
This investment was subsequently repaid in the fourth quarter of 2015.
Xlumena, Inc.  On April 2, 2015, we acquired Xlumena, Inc.  (Xlumena), a medical device company that developed minimally invasive devices for Endoscopic Ultrasound (EUS) guided transluminal drainage of targeted areas within the gastrointestinal tract.
The purchase agreement called for an upfront payment of $63 million, an additional payment of $13 million upon FDA clearance of the HOT AXIOS?
Product, and further sales-based milestones based on sales achieved through 2018.
In 2016, we completed the integration of Xlumena into our Endoscopy business.
In addition, we completed other acquisitions during 2015 for total consideration of $6 million in cash at closing plus contingent consideration of up to $1 million.
Incremental contract start-up costs—large municipal contract.
During 2018 and 2017, we incurred costs of $5.7 million and $8.2 million, respectively, related to the implementation of a large municipal contract.
These costs did not meet the capitalization criteria prescribed by the new revenue recognition standard.
Adoption of the Tax Act.
The Tax Act was enacted on December 22, 2017.
Among other things, the Tax Act reduced the U. S.  federal corporate tax rate from 35% to 21%.
For the year ended December 31, 2017, we recorded provisional amounts based on our estimates of the Tax Act’s effect to our deferred taxes, uncertain tax positions, and one-time transition tax.
These adjustments reduced our tax provision by $463.9 million.
During 2018, we adjusted the provisional amounts recorded as of December 31, 2017 for the one-time transition tax, deferred taxes and uncertain tax positions.
These adjustments increased our tax provision by $0.3 million.
Bridgeton insurance recovery, net.
During 2018, we collected an insurance recovery of $40.0 million related to our closed Bridgeton Landfill in Missouri, which we recognized as a reduction of remediation expenses in our cost of operations.
In addition, we incurred $12.0 million of incremental costs attributable to the Bridgeton insurance recovery.
Recent Developments 2019 Financial Guidance In 2019, we will continue to focus on managing the controllable aspects of our business by enhancing the quality of our revenue, investing in profitable growth opportunities and reducing costs.
Our team remains focused on executing our strategy to deliver consistent earnings and free cash flow growth, and improve return on invested capital.
We are committed to an efficient capital structure, maintaining our investment grade credit ratings and increasing cash returned to our shareholders.
Our guidance is based on current economic conditions and does not assume any significant changes in the overall economy in 2019.
Specific guidance follows: Revenue We expect 2019 revenue to increase by approximately 4.25 to 4.75% comprised of the following:

<table><tr><td></td><td>Amount(in millions)</td><td>IssuanceDate</td><td>Maturity Date</td><td>Semi-annualCoupon Rate</td></tr><tr><td>January 2017 Notes</td><td>$250</td><td>November 2004</td><td>January 2017</td><td>5.125%</td></tr><tr><td>October 2018 Notes</td><td>600</td><td>August 2013</td><td>October 2018</td><td>2.650%</td></tr><tr><td>January 2020 Notes</td><td>850</td><td>December 2009</td><td>January 2020</td><td>6.000%</td></tr><tr><td>May 2020 Notes</td><td>600</td><td>May 2015</td><td>May 2020</td><td>2.850%</td></tr><tr><td>May 2022 Notes</td><td>500</td><td>May 2015</td><td>May 2022</td><td>3.375%</td></tr><tr><td>May 2025 Notes</td><td>750</td><td>May 2015</td><td>May 2025</td><td>3.850%</td></tr><tr><td>October 2023 Notes</td><td>450</td><td>August 2013</td><td>October 2023</td><td>4.125%</td></tr><tr><td>November 2035 Notes</td><td>350</td><td>November 2005</td><td>November 2035</td><td>6.250%</td></tr><tr><td>January 2040 Notes</td><td>300</td><td>December 2009</td><td>January 2040</td><td>7.375%</td></tr><tr><td></td><td>$4,650</td><td></td><td></td><td></td></tr></table>
<table><tr><td>(in millions)</td><td>2017</td><td>2018</td><td>2019</td><td>2020</td><td>2021</td><td>Thereafter</td><td>Total</td></tr><tr><td>Long-term debt obligations</td><td>$250</td><td>$825</td><td>$150</td><td>$1,825</td><td>$—</td><td>$2,350</td><td>$5,400</td></tr><tr><td>Interest payments -1</td><td>224</td><td>216</td><td>194</td><td>151</td><td>111</td><td>899</td><td>1,795</td></tr><tr><td>Lease obligations -1</td><td>66</td><td>60</td><td>42</td><td>34</td><td>25</td><td>64</td><td>291</td></tr><tr><td>Purchase obligations -1</td><td>321</td><td>52</td><td>39</td><td>19</td><td>12</td><td>15</td><td>458</td></tr><tr><td>Minimum royalty obligations -1</td><td>1</td><td>2</td><td>1</td><td>2</td><td>1</td><td>1</td><td>8</td></tr><tr><td>Legal reserves</td><td>1,062</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>1,062</td></tr><tr><td>Unrecognized tax benefits -2</td><td>577</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>577</td></tr><tr><td></td><td>$2,501</td><td>$1,155</td><td>$426</td><td>$2,031</td><td>$149</td><td>$3,329</td><td>$9,591</td></tr></table>
<table><tr><td>Cash, net of cash acquired</td><td>$366</td></tr><tr><td>Fair value of contingent consideration</td><td>50</td></tr><tr><td>Fair value of debt repaid</td><td>43</td></tr><tr><td></td><td>$459</td></tr></table>
<table><tr><td>Goodwill</td><td>$208</td></tr><tr><td>Amortizable intangible assets</td><td>228</td></tr><tr><td>Inventory</td><td>11</td></tr><tr><td>Property, plant and equipment</td><td>6</td></tr><tr><td>Other net liabilities</td><td>-2</td></tr><tr><td>Deferred income taxes</td><td>8</td></tr><tr><td></td><td>$459</td></tr></table>
<table><tr><td></td><td>AmountAssigned(in millions)</td><td>WeightedAverageAmortizationPeriod(in years)</td><td>Range of Risk-Adjusted DiscountRates used inPurchase PriceAllocation</td></tr><tr><td>Amortizable intangible assets:</td><td></td><td></td><td></td></tr><tr><td>Technology-related</td><td>$176</td><td>9-13</td><td>11% - 20%</td></tr><tr><td>Customer relationships</td><td>51</td><td>9-13</td><td>11% - 12%</td></tr><tr><td>Other intangible assets</td><td>1</td><td>4</td><td>11%</td></tr><tr><td></td><td>$228</td><td></td><td></td></tr></table>

Question: what is the ratio of the insurance recovery to the incremental cost related to our closed bridgeton landfill
Answer: 3.33333